These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 3545448)

  • 1. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
    Yavelow J; Caggana M; Beck KA
    Cancer Res; 1987 Mar; 47(6):1598-601. PubMed ID: 3545448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential intracellular target proteins of the anticarcinogenic Bowman Birk protease inhibitor identified by affinity chromatography.
    Billings PC; St Clair W; Owen AJ; Kennedy AR
    Cancer Res; 1988 Apr; 48(7):1798-802. PubMed ID: 3280120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor.
    Billings PC; Habres JM; Liao DC; Tuttle SW
    Cancer Res; 1991 Oct; 51(20):5539-43. PubMed ID: 1913672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
    Chen YW; Huang SC; Lin-Shiau SY; Lin JK
    Carcinogenesis; 2005 Jul; 26(7):1296-306. PubMed ID: 15746161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
    Ware JH; Wan XS; Rubin H; Schechter NM; Kennedy AR
    Arch Biochem Biophys; 1997 Aug; 344(1):133-8. PubMed ID: 9244390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity.
    Malkowicz SB; Liu SP; Broderick GA; Wein AJ; Kennedy AR; Levin RM
    Neurourol Urodyn; 2003; 22(1):54-7. PubMed ID: 12478602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of 3-methylcholanthrene-induced cellular transformation by timed administration of the Bowman-Birk protease inhibitor.
    St Clair WH
    Carcinogenesis; 1991 May; 12(5):935-7. PubMed ID: 2029760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of oral carcinogenesis by a protease inhibitor.
    Messadi DV; Billings P; Shklar G; Kennedy AR
    J Natl Cancer Inst; 1986 Mar; 76(3):447-52. PubMed ID: 3081747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete amino acid sequence of the lentil trypsin-chymotrypsin inhibitor LCI-1.7 and a discussion of atypical binding sites of Bowman-Birk inhibitors.
    Weder JK; Hinkers SC
    J Agric Food Chem; 2004 Jun; 52(13):4219-26. PubMed ID: 15212472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro inhibition of the activation of Pro-matrix Metalloproteinase 1 (Pro-MMP-1) and Pro-matrix metalloproteinase 9 (Pro-MMP-9) by rice and soybean Bowman-Birk inhibitors.
    Bawadi HA; Antunes TM; Shih F; Losso JN
    J Agric Food Chem; 2004 Jul; 52(15):4730-6. PubMed ID: 15264907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro.
    Yavelow J; Collins M; Birk Y; Troll W; Kennedy AR
    Proc Natl Acad Sci U S A; 1985 Aug; 82(16):5395-9. PubMed ID: 3860869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells.
    Ware JH; Wan XS; Kennedy AR
    Nutr Cancer; 1999; 33(2):174-7. PubMed ID: 10368813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells.
    Zhang L; Wan XS; Donahue JJ; Ware JH; Kennedy AR
    Nutr Cancer; 1999; 33(2):165-73. PubMed ID: 10368812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR; Szuhaj BF; Newberne PM; Billings PC
    Nutr Cancer; 1993; 19(3):281-302. PubMed ID: 8346077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiapoptotic activity of the Bowman-Birk inhibitor can be attributed to copurified phospholipids.
    Foehr MW; Tomei LD; Goddard JG; Pemberton PA; Bathurst IC
    Nutr Cancer; 1999; 34(2):199-205. PubMed ID: 10578488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a soluble enzyme from C3H/10T1/2 cells which is inhibited by the Bowman-Birk proteinase inhibitor.
    Fagan JM; Waxman L
    Biochem Biophys Res Commun; 1991 Aug; 178(3):856-61. PubMed ID: 1872865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteinase inhibition using small Bowman-Birk-type structures.
    Fernandez JH; Mello MO; Galgaro L; Tanaka AS; Silva-Filho MC; Neshich G
    Genet Mol Res; 2007 Oct; 6(4):846-58. PubMed ID: 18058707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteases, protease inhibitors and radiation carcinogenesis.
    Kennedy AR
    Int J Radiat Biol; 2023; 99(6):882-890. PubMed ID: 34325613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of carcinogenesis by protease inhibitors.
    Kennedy AR
    Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans.
    Birk Y
    Int J Pept Protein Res; 1985 Feb; 25(2):113-31. PubMed ID: 3886572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.